184 related articles for article (PubMed ID: 37327541)
1. Efficacy analysis of single-agent carboplatin AUC4 2-weekly as second-line therapy for methotrexate-resistant (MTX-R) low risk gestational trophoblastic neoplasia (GTN).
Winter MC; Tidy JA; Singh K; Sarwar N; Aguiar X; Seckl MJ
Gynecol Oncol; 2023 Aug; 175():66-71. PubMed ID: 37327541
[TBL] [Abstract][Full Text] [Related]
2. Risk adapted single-agent dactinomycin or carboplatin for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia.
Winter MC; Tidy JA; Hills A; Ireson J; Gillett S; Singh K; Hancock BW; Coleman RE
Gynecol Oncol; 2016 Dec; 143(3):565-570. PubMed ID: 27756557
[TBL] [Abstract][Full Text] [Related]
3. Increasing the human chorionic gonadotrophin cut-off to ≤1000 IU/l for starting actinomycin D in post-molar gestational trophoblastic neoplasia developing resistance to methotrexate spares more women multi-agent chemotherapy.
Cortés-Charry R; Hennah L; Froeling FEM; Short D; Aguiar X; Tin T; Harvey R; Unsworth N; Kaur B; Savage P; Sarwar N; Seckl MJ
ESMO Open; 2021 Jun; 6(3):100110. PubMed ID: 33845362
[TBL] [Abstract][Full Text] [Related]
4. Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia?
Mora PAR; Sun SY; Velarde GC; Filho JR; Uberti EH; Dos Santos Esteves APV; Elias KM; Horowitz NS; Braga A; Berkowitz RS
Gynecol Oncol; 2019 May; 153(2):277-285. PubMed ID: 30857648
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for second-line dactinomycin failure after methotrexate treatment for low-risk gestational trophoblastic neoplasia: a retrospective study.
Hoeijmakers YM; Sweep F; Lok C; Ottevanger PB
BJOG; 2020 Aug; 127(9):1139-1145. PubMed ID: 32141676
[TBL] [Abstract][Full Text] [Related]
6. Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?
Miller CR; Chappell NP; Sledge C; Leath CA; Phippen NT; Havrilesky LJ; Barnett JC
Gynecol Oncol; 2017 Jan; 144(1):125-129. PubMed ID: 27816248
[TBL] [Abstract][Full Text] [Related]
7. Flat-dose versus weight or body surface area-based methotrexate dosing in low-risk gestational trophoblastic neoplasia.
Parker VL; Cushen BF; Hills A; Kandiah K; Palmer JE; Singh K; Hancock BW; Tidy JA; Winter MC
Gynecol Oncol; 2023 Feb; 169():34-40. PubMed ID: 36495594
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and toxicity of second-line actinomycin D in patients with methotrexate-resistant postmolar low-risk gestational trophoblastic neoplasia.
Maestá I; Nitecki R; Desmarais CCF; Horowitz NS; Goldstein DP; Elias KM; Berkowitz RS
Gynecol Oncol; 2020 May; 157(2):372-378. PubMed ID: 32037196
[TBL] [Abstract][Full Text] [Related]
9. A 30-year experience in using oral methotrexate as initial treatment for gestational trophoblastic neoplasia regardless of risk group.
Faaborg L; Niemann I; Ostenfeld EB; Hansen ES; Sunde L; Lindegaard JC
Acta Oncol; 2016; 55(2):234-9. PubMed ID: 26106854
[TBL] [Abstract][Full Text] [Related]
10. Human chorionic gonadotropin (hCG) regression normograms for patients with high-risk gestational trophoblastic neoplasia treated with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapy.
Lybol C; Westerdijk K; Sweep FCGJ; Ottevanger PB; Massuger LFAG; Thomas CMG
Ann Oncol; 2012 Nov; 23(11):2903-2906. PubMed ID: 22730100
[TBL] [Abstract][Full Text] [Related]
11. M-EA (methotrexate, etoposide, dactinomycin) and EMA-CO (methotrexate, etoposide, dactinomycin / cyclophosphamide, vincristine) regimens as first-line treatment of high-risk gestational trophoblastic neoplasia.
Singh K; Gillett S; Ireson J; Hills A; Tidy JA; Coleman RE; Hancock BW; Winter MC
Int J Cancer; 2021 May; 148(9):2335-2344. PubMed ID: 33210289
[TBL] [Abstract][Full Text] [Related]
12. Predictive factors associated with resistance to initial methotrexate treatment in women with low-risk gestational trophoblastic neoplasia.
Phianpiset R; Ruengkhachorn I; Kuljarusnont S; Jareemit N; Udompunturak S
Asia Pac J Clin Oncol; 2022 Oct; 18(5):e495-e506. PubMed ID: 35253996
[TBL] [Abstract][Full Text] [Related]
13. Outcome of gestational trophoblastic neoplasia: experience from a tertiary cancer centre in India.
Gulia S; Bajpai J; Gupta S; Maheshwari A; Deodhar K; Kerkar RA; Seth V; Rekhi B; Menon S
Clin Oncol (R Coll Radiol); 2014 Jan; 26(1):39-44. PubMed ID: 24051171
[TBL] [Abstract][Full Text] [Related]
14. Human Chorionic Gonadotropin (hCG) Regression Curve for Predicting Response to EMA/CO (Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide and Vincristine) Regimen in Gestational Trophoblastic Neoplasia.
Rattanaburi A; Boonyapipat S; Supasinth Y
Asian Pac J Cancer Prev; 2015; 16(12):5037-41. PubMed ID: 26163637
[TBL] [Abstract][Full Text] [Related]
15. Treatment of low-risk gestational trophoblastic neoplasia.
Winter MC
Best Pract Res Clin Obstet Gynaecol; 2021 Jul; 74():67-80. PubMed ID: 33741258
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy initiation with single-course methotrexate alone or combined with dactinomycin versus multi-course methotrexate for low-risk gestational trophoblastic neoplasia: a multi-centric randomized clinical trial.
Chen L; Xi L; Jiang J; Yin R; Qu P; Li X; Wan X; Chen Y; Hu D; Mao Y; Pan Z; Cheng X; Wang X; Li Q; Weng D; Zhang X; Zhang H; Ping Q; Liu X; Xie X; Kong B; Ma D; Lu W
Front Med; 2022 Apr; 16(2):276-284. PubMed ID: 34181195
[TBL] [Abstract][Full Text] [Related]
17. Treatment of high-risk gestational trophoblastic neoplasia with weekly high-dose methotrexate-etoposide.
Han SN; Amant F; Leunen K; Devi UK; Neven P; Berteloot P; Vergote I
Gynecol Oncol; 2012 Oct; 127(1):47-50. PubMed ID: 22705360
[TBL] [Abstract][Full Text] [Related]
18. First-line chemotherapy in low-risk gestational trophoblastic neoplasia.
Lawrie TA; Alazzam M; Tidy J; Hancock BW; Osborne R
Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD007102. PubMed ID: 27281496
[TBL] [Abstract][Full Text] [Related]
19. The 16-year experience in treating low-risk gestational trophoblastic neoplasia patients with failed primary methotrexate chemotherapy.
Wu X; Qin J; Shen T; Fei W; Chen L; Xie X; Lu W
J Gynecol Oncol; 2020 Jul; 31(4):e36. PubMed ID: 32026657
[TBL] [Abstract][Full Text] [Related]
20. Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000.
McNeish IA; Strickland S; Holden L; Rustin GJ; Foskett M; Seckl MJ; Newlands ES
J Clin Oncol; 2002 Apr; 20(7):1838-44. PubMed ID: 11919242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
